Astera Labs
ALAB
382.25
-7.55
-1.94%
Astera Labs
US · ALAB
#366 by market cap
Listed 2024
382.25
-7.55
-1.94%
Live - 5344 symbols - heartbeat 53s ago
· 2026-10-08 07:00
Pre-market
372.31
-2.60%
After-hours
385.99
+0.98%
Overnight
374.02
-2.15%
- Market cap
- 66.31B
- P/E (TTM)i
- 188.30
- P/Bi
- 38.43
- EPSi
- 1.22
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on ALAB?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 238.47, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 4 years
Latest year +115.13% YoY
Margins
- Gross margin
- 75.69%
- Operating margin
- 20.34%
- Net margin
- 25.70%
Key ratios & quality
- Altman Z-Scorei
- 238.47
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 79.87M | 115.79M | 396.29M | 852.53M |
| Gross profit | 58.68M | 79.83M | 302.70M | 645.26M |
| Selling & admin expenses | 45.16M | 35.92M | 217.94M | 167.84M |
| Research & development | 73.71M | 73.41M | 200.83M | 304.00M |
| Operating profit | -60.19M | -29.50M | -116.07M | 173.42M |
| Pretax profit | -57.58M | -22.95M | -81.78M | 218.15M |
| Tax | 764.00K | 3.31M | 1.64M | -981.00K |
| Net profit | -58.35M | -26.26M | -83.42M | 219.13M |
| Basic EPS | 0 | 0 | -1 | 1 |
| Diluted EPS | -0.45 | -0.17 | -0.64 | 1.22 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 159.44M | 191.93M | 230.58M | 270.58M | 308.36M | 392.40M |
| Gross profit | 119.41M | 145.56M | 175.81M | 204.48M | 235.14M | 287.57M |
| Selling & admin expenses | 43.57M | 39.07M | 41.48M | 43.73M | 47.67M | 62.42M |
| Research & development | 64.55M | 66.72M | 78.93M | 93.79M | 125.63M | 135.90M |
| Operating profit | 11.29M | 39.77M | 55.41M | 66.96M | 61.83M | 89.25M |
| Pretax profit | 21.72M | 50.66M | 66.86M | 78.92M | 73.41M | 102.83M |
| Tax | -10.10M | -560.00K | -24.25M | 33.93M | -6.90M | -50.26M |
| Net profit | 31.82M | 51.22M | 91.11M | 44.98M | 80.31M | 153.09M |
| Basic EPS | 0 | 0 | 1 | 0 | 0 | 1 |
| Diluted EPS | 0.18 | 0.29 | 0.50 | 0.25 | 0.44 | 0.83 |
Balance sheet
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total current assets | 206.01M | 185.81M | 1.01B | 1.36B |
| Cash & ST investments | 163.14M | 149.31M | 914.30M | 1.19B |
| Inventory | 28.87M | 24.10M | 43.22M | 58.98M |
| Total assets | 211.73M | 196.29M | 1.05B | 1.53B |
| Total current liabilities | 40.09M | 35.08M | 86.54M | 133.04M |
| Short-term debt | 1.60M | 2.16M | 1.29M | 4.15M |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | 297,023,000.00 | 293,993,000.00 | 89,709,000.00 | 168,189,000.00 |
| Total equity | -85.29M | -97.70M | 964.80M | 1.36B |
| Retained earnings | -99.12M | -125.38M | -208.80M | 10.34M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.08B | 1.18B | 1.29B | 1.36B | 1.41B | 1.65B |
| Cash & ST investments | 924.73M | 1.07B | 1.13B | 1.19B | 1.18B | 1.25B |
| Inventory | 51.06M | 58.60M | 51.66M | 58.98M | 60.16M | 113.78M |
| Total assets | 1.12B | 1.27B | 1.40B | 1.53B | 1.66B | 1.93B |
| Total current liabilities | 77.28M | 106.38M | 100.96M | 133.04M | 125.04M | 164.31M |
| Short-term debt | -- | -- | -- | 4.15M | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 80,132,000.00 | 135,691,000.00 | 129,451,000.00 | 168,189,000.00 | 165,267,000.00 | 205,797,000.00 |
| Total equity | 1.04B | 1.14B | 1.27B | 1.36B | 1.49B | 1.73B |
| Retained earnings | -176.98M | -125.76M | -34.64M | 10.34M | 90.65M | 243.74M |
Cash flow
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -35.90M | -12.72M | 136.68M | 319.31M |
| Depreciation & amortization | 807.00K | 1.78M | 3.15M | 6.83M |
| Free cash flow | -39.77M | -15.48M | 102.43M | 281.76M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -313.00K | -210.00K | 671.13M | 0 |
| Ending cash balance | 76.09M | 45.10M | 80.04M | 167.68M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 10.50M | 135.37M | 78.17M | 95.27M | 74.60M | 87.68M |
| Depreciation & amortization | 1.13M | 1.39M | 1.47M | 2.85M | 3.71M | 3.93M |
| Free cash flow | 5.97M | 133.34M | 65.88M | 76.58M | 67.01M | 67.21M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | -- | -- |
| Ending cash balance | 86.99M | 163.40M | 141.48M | 167.68M | 148.36M | 111.52M |
Returns & efficiency
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROE %i | -- | -- | -19.24 | 18.82 |
| ROA %i | -27.56 | -12.87 | -13.34 | 16.95 |
| ROIC %i | -- | -- | -25.02 | 15.93 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -75.36 | -25.47 | -29.29 | 20.34 |
| FCF / sales %i | -- | -- | 25.85 | 33.05 |
| Current ratioi | 5.14 | 5.30 | 11.71 | 10.24 |
| Quick ratioi | 4.34 | 4.49 | 11.01 | 9.56 |
| Debt / assetsi | 0.75 | 1.10 | 0.12 | 0.27 |
| LT debt / equityi | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 120.18 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 4.47 | 10.11 | 18.40 | 18.82 | 21.11 | 25.83 |
| ROA %i | 4.17 | 9.16 | 16.68 | 16.95 | 19.25 | 23.07 |
| ROIC %i | 1.08 | 6.90 | 15.42 | 15.93 | 17.52 | 23.79 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -4.45 | 6.99 | 14.74 | 20.34 | 22.36 | 22.75 |
| FCF / sales %i | 22.05 | 34.74 | 31.73 | 33.05 | 34.23 | 23.02 |
| Current ratioi | 13.92 | 11.10 | 12.78 | 10.24 | 11.30 | 10.05 |
| Quick ratioi | 12.87 | 10.24 | 11.66 | 9.56 | 10.55 | 9.16 |
| Debt / assetsi | -- | -- | -- | 0.27 | -- | -- |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Product sales100.00%
Region
Singapore32.49%
China30.06%
Taiwan29.03%
Other5.21%
United States3.22%
Quote time 2026-10-08 07:00:12 · For reference only, not investment advice and not tailored to your situation.